J&J-backed startup Rapport files for US IPO

05:21pm, Friday, 17'th May 2024
Biopharmaceutical company Rapport Therapeutics, backed by the venture capital arm of Johnson & Johnson , filed for an initial public offering in the United States on Friday.
Johnson & Johnson (JNJ) inks deal to acquire Proteologix, Inc. for $850 million in cash. The transaction is expected to be closed in mid-2024.
Finding equities with the potential for steady, long-term development is crucial. These seven prospects span a variety of industries and offer solid arguments for long-term investment.

3 Cheap Healthcare Stocks to Buy Now: May 2024

06:30am, Friday, 17'th May 2024
With the market rally broadening out, value sectors are beginning to catch a bid. Healthcare deserves consideration as one of the value sectors presenting some bargains in this overheating market.

7 Upcoming Dividend Increases Including A King

12:50pm, Thursday, 16'th May 2024
Johnson & Johnson extends its 62-year streak of dividend increases with a 4.2% annual increase. Other companies on the list have streaks ranging from 7 to 21 years, with an average increase of 6.3%. T
Johnson & Johnson (JNJ) reported earnings 30 days ago. What's next for the stock?
On 5/20/24, Nuvei, Walgreens Boots Alliance, and Johnson & Johnson will all trade ex-dividend for their respective upcoming dividends. Nuvei will pay its quarterly dividend of $0.10 on 6/6/24, Walgree
Johnson & Johnson on Thursday said it would acquire privately held Proteologix for $850 million in cash, with potential for an additional milestone payment.
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) announced today that it has entered into a definitive agreement to acquire Proteologix, Inc., a privately-held biotechnology company
After covering essentials, consumers spend on discretionary items. But it's the consumer staples items that make up the essential part of any budget.
Johnson & Johnson (NYSE:JNJ ) BofA Securities Health Care Conference Transcript May 14, 2024 4:40 PM ET Executives John Reed - Executive Vice President, Innovative Medicine, R&D Analysts Geoff Meacham
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
We believe that the pharmaceuticals bellwether Johnson & Johnson (NYSE: JNJ) is currently a better pick over its peer Merck (NYSE: MRK). Although Merck trades at a higher valuation of 5.5x trailing re
Johnson & Johnson JNJ, +0.29% rolled out a four-part bond on Monday to help fund its planned $13 billion acquisition of Shockwave Medical, underscoring how the Federal Reserve's rate hikes haven't dul
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE